Alpha Tau Medical Ltd. (NASDAQ:DRTSW – Get Rating) was the recipient of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 11,600 shares, a drop of 8.7% from the March 31st total of 12,700 shares. Based on an average trading volume of 8,300 shares, the days-to-cover ratio is presently 1.4 days.
Alpha Tau Medical Stock Up 1.9 %
Shares of Alpha Tau Medical stock traded up $0.00 during trading on Wednesday, hitting $0.22. 1,775 shares of the stock traded hands, compared to its average volume of 14,604. Alpha Tau Medical has a twelve month low of $0.18 and a twelve month high of $1.00. The company has a fifty day moving average price of $0.30 and a two-hundred day moving average price of $0.32.
Get Alpha Tau Medical alerts:Institutional Investors Weigh In On Alpha Tau Medical
Several institutional investors have recently made changes to their positions in DRTSW. LMR Partners LLP raised its stake in shares of Alpha Tau Medical by 67.4% in the 3rd quarter. LMR Partners LLP now owns 112,986 shares of the company's stock valued at $660,000 after acquiring an additional 45,500 shares in the last quarter. Whitebox Advisors LLC bought a new position in shares of Alpha Tau Medical in the 3rd quarter valued at approximately $65,000. Walleye Capital LLC raised its stake in shares of Alpha Tau Medical by 10.9% in the 2nd quarter. Walleye Capital LLC now owns 204,285 shares of the company's stock valued at $98,000 after acquiring an additional 20,096 shares in the last quarter. Chicago Partners Investment Group LLC bought a new position in shares of Alpha Tau Medical in the 1st quarter valued at approximately $55,000. Finally, Walleye Trading LLC bought a new position in shares of Alpha Tau Medical in the 1st quarter valued at approximately $65,000.
Alpha Tau Medical Company Profile
(Get Rating)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers.
Read More
- Get a free copy of the StockNews.com research report on Alpha Tau Medical (DRTSW)
- Starbucks Stock Becomes a Value Play
- Kraft Heinz Recovery Gains Momentum
- Here's Why AMD's Weak Guidance Is A Blessing In Disguise
- BP Shares Sold Off After Earnings: Here Is What Upset Markets
- Will Forced Divesture Of Grail Boost Illumina Shareholder Value?
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.